These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 28255739)

  • 1. Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study.
    Desplats M; Pascart T; Jelin G; Norberciak L; Philippe P; Houvenagel E; Goeb V; Flipo RM
    Clin Rheumatol; 2017 Jun; 36(6):1395-1400. PubMed ID: 28255739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK).
    Mueller RB; Gengenbacher M; Richter S; Dudler J; Möller B; von Kempis J
    Arthritis Res Ther; 2016 Apr; 18():88. PubMed ID: 27074795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An unfavourable outcome following switching intravenous abatacept and tocilizumab to subcutaneous forms during the COVID-19 pandemic.
    Gupta R; Shipa M; Yeoh SA; Buck P; Ehrenstein MR
    Rheumatology (Oxford); 2021 Feb; 60(2):977-979. PubMed ID: 33232489
    [No Abstract]   [Full Text] [Related]  

  • 4. Subcutaneous tocilizumab: recent advances for the treatment of rheumatoid arthritis.
    Ogata A; Kato Y; Higa S; Maeda K
    Expert Opin Drug Deliv; 2019 Jun; 16(6):639-648. PubMed ID: 31088167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate.
    Genovese MC; Covarrubias A; Leon G; Mysler E; Keiserman M; Valente R; Nash P; Simon-Campos JA; Porawska W; Box J; Legerton C; Nasonov E; Durez P; Aranda R; Pappu R; Delaet I; Teng J; Alten R
    Arthritis Rheum; 2011 Oct; 63(10):2854-64. PubMed ID: 21618201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching from intravenous to subcutaneous formulation of abatacept: a single-center Italian experience on efficacy and safety.
    Reggia R; Franceschini F; Tincani A; Cavazzana I
    J Rheumatol; 2015 Feb; 42(2):193-5. PubMed ID: 25512476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cost-minimization analysis of subcutaneous abatacept in the treatment of rheumatoid arthritis in Spain].
    Ariza R; Van Walsem A; Canal C; Roldán C; Betegón L; Oyagüez I; Janssen K
    Farm Hosp; 2014 Jul; 38(4):257-65. PubMed ID: 25137158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous vs intravenous abatacept in rheumatoid arthritis-interstitial lung disease. National multicentre study of 397 patients.
    López-Maraver M; Serrano-Combarro A; Atienza-Mateo B; Del Val N; Casafont-Solé I; Melero-Gonzalez RB; Pérez-Linaza A; Calvo Gutiérrez J; Mena-Vázquez N; Vegas-Revenga N; Domínguez-Casas L; Loarce Martos J; Peralta Ginés CA; Diez Morrondo C; Pérez Albaladejo L; López Sánchez R; Manzano Canabal MG; Brandy-García AM; López Viejo P; Bonilla G; Maiz-Alonso O; Carrasco-Cubero C; Garijo Bufort M; Moreno M; Urruticoechea-Arana A; Ordóñez-Palau S; González-Montagut C; Giner Serret E; De Dios Jiménez De Aberasturi JR; Lozano Morillo F; Vázquez Rodríguez T; Carreira PE; Blanco Madrigal JM; Miguel Ibáñez B; Rodríguez López M; Fernández-Díaz C; Loricera J; Ferraz-Amaro I; Ferrer-Pargada D; Castañeda S; Blanco R;
    Semin Arthritis Rheum; 2024 Oct; 68():152517. PubMed ID: 39067148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA).
    Burmester GR; Rubbert-Roth A; Cantagrel A; Hall S; Leszczynski P; Feldman D; Rangaraj MJ; Roane G; Ludivico C; Bao M; Rowell L; Davies C; Mysler EF
    Ann Rheum Dis; 2016 Jan; 75(1):68-74. PubMed ID: 26056119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of switching from intravenous to subcutaneous formulation of tocilizumab in patients with rheumatoid arthritis.
    Iwamoto N; Fukui S; Umeda M; Nishino A; Nakashima Y; Suzuki T; Horai Y; Nonaka F; Okada A; Koga T; Kawashiri SY; Fujikawa K; Aramaki T; Ichinose K; Hirai Y; Tamai M; Nakamura H; Terada K; Nakashima M; Mizokami A; Origuchi T; Eguchi K; Ueki Y; Kawakami A
    Mod Rheumatol; 2016 Sep; 26(5):662-6. PubMed ID: 26708444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis.
    D'Agostino MA; Alten R; Mysler E; Le Bars M; Ye J; Murthy B; Heitzmann J; Vadanici R; Ferraccioli G
    Clin Rheumatol; 2017 Dec; 36(12):2655-2665. PubMed ID: 28822046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety profile of intravenous tocilizumab versus intravenous abatacept in treating female Saudi Arabian patients with active moderate-to-severe rheumatoid arthritis.
    Elmedany SH; Mohamed AE; Galil SMA
    Clin Rheumatol; 2019 Aug; 38(8):2109-2117. PubMed ID: 30915650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
    McLaughlin M; Östör A
    Expert Opin Drug Saf; 2015 Mar; 14(3):429-37. PubMed ID: 25553607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study.
    Keystone EC; Kremer JM; Russell A; Box J; Abud-Mendoza C; Elizondo MG; Luo A; Aranda R; Delaet I; Swanink R; Gujrathi S; Luggen M
    Ann Rheum Dis; 2012 Jun; 71(6):857-61. PubMed ID: 22302417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, safety, pharmacokinetics and immunogenicity of abatacept administered subcutaneously or intravenously in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate: a Phase II/III, randomized study.
    Iwahashi M; Inoue H; Matsubara T; Tanaka T; Amano K; Kanamono T; Nakano T; Uchimura S; Izumihara T; Yamazaki A; Karyekar CS; Takeuchi T
    Mod Rheumatol; 2014 Nov; 24(6):885-91. PubMed ID: 24708204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustainable Efficacy of Switching From Intravenous to Subcutaneous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis.
    Ogata A; Atsumi T; Fukuda T; Hirabayashi Y; Inaba M; Ishiguro N; Kai M; Kawabata D; Kida D; Kohsaka H; Matsumura R; Minota S; Mukai M; Sumida T; Takasugi K; Tamaki S; Takeuchi T; Ueda A; Yamamoto K; Yamanaka H; Yoshifuji H; Nomura A;
    Arthritis Care Res (Hoboken); 2015 Oct; 67(10):1354-62. PubMed ID: 25832859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient satisfaction and clinical effectiveness of switching from intravenous tocilizumab to subcutaneous tocilizumab in patients with juvenile idiopathic arthritis: an observational study.
    Ayaz NA; Karadağ ŞG; Koç R; Demirkan FG; Çakmak F; Sönmez HE
    Rheumatol Int; 2020 Jul; 40(7):1111-1116. PubMed ID: 32417938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population Pharmacokinetics and Exposure-Response Relationship of Intravenous and Subcutaneous Abatacept in Patients With Rheumatoid Arthritis.
    Li X; Roy A; Murthy B
    J Clin Pharmacol; 2019 Feb; 59(2):245-257. PubMed ID: 30229926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial.
    Genovese MC; Tena CP; Covarrubias A; Leon G; Mysler E; Keiserman M; Valente R; Nash P; Simon-Campos JA; Box J; Legerton CW; Nasonov E; Durez P; Delaet I; Teng J; Alten R
    J Rheumatol; 2014 Apr; 41(4):629-39. PubMed ID: 24584926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Choice of the most appropriate biological disease-modifying anti-rheumatic drug for injection spacing: results from a multicentre observational study.
    Matsuno H; Katayama K; Funahashi K; Saitoh M; Matsubara T
    Clin Exp Rheumatol; 2020; 38(3):398-404. PubMed ID: 31287398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.